[Seite 30↓]

Literatur der Einführung und Zielstellung

Armand J, Quick P. Teleangiectasia: Its Relationship to the Minot-Von Willebrand Syndrome. The American Journal of the Medical Sciences. 1967; 11: 585-601.

Barber A, Green D, Galluzzo T, Tsào CH. The bleeding time as a preoperative screening test. Am J Med 1985; 78: 761-764.

Bekanntmachung des Paul-Ehrlich-Institutes (PEI): Bericht zur Meldung nach § 21 TFG für die Jahre 1999 und 2000 Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2003; 46: 1016–1032

Blackburn EK. Primary capillary haemorrhage (including von Willebrand`s Disease). Brit. J. Haemat. 1961; 7: 239-249.

Blombäck M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosing mild von Willebrand`s Disease. Am. J. Hematol. 1992; 40: 117-120.

Böck M, De Haan J, Beck KH, Gutensohn K, Hertfelder HJ, Karger R, Heim MU, Beeser H, Weber D, Kretschmer V. Standardization of the PFA-100® platelet function test in 105 mmol/l bufffered citrate : effect of gender, smoking, and oral contraceptives. Br J Haematol 1999; 106: 898-904.

Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-928.

Borzotta AP, Keeling MM.. Value of the preoperative history as an indicator of hemostatic disorders. Ann Surg 1984; 200: 648-652.

Bowie EJW. Recognition of easily missed bleeding diseases. Mayo Clin Proc 1982; 57: 263-264.

Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmermann TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-315.

Cattaneo M, Harris A, Strömberg U et al. The effect of Desmopressin on Reducing Blood Loss in Cardiac Surgery – A Meta-Analysis of double-blind, placebo-controlled trials. Thromb Hemost 1995; 74: 1064.

Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82 (1): 35-39

Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999; 96: 213-217.

Chard R, Kam C, Nunn G et al. Use of desmopressin in the management of aspirin related and intractable hemorrhage after cardiopulmonary bypass. Aust NZ J Surg 1990; 60: 125.

Despotis GJ, Levine V, Filos KS: Evaluation of a new, point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85: 1311-1323.

Eika C, Havig O, Godal HC. The value of preoperative haemostatic screening. Scand J Haematol 1978; 21: 349-354.

Flordal PA. Use of desmopressin to prevent bleeding in surgery. Eur J Surg 1998; 164: 5.

Fremes SE. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58: 1580.


[Seite 31↓]

Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyser using high shear stress. A study of 60 cases. Blood 1998, 91: 1325.

Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs, Drug Research 1983; 33: 479.

George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27-39.

Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10: 25-31.

Horrow JC, van Riper DF, Strong MD et al. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991; 84: 2063.

Houry S, Georgeac C, Hay JM, Fingerhut A, Boudet JJ. A prospective multicenter evaluation of preoperative hemostatic screening tests. The American Journal of Surgery 1995; 170: 75-84.

Kaplan E. Sheiner L, Boeckmann A, Roizen M, Beal S, Cohen S, Nicoll D. The usefulness of preoperative laboratory screening. JAMA 1985; 253: 3576-3581.

Kerényi A, Schlammadinger Á, Ajzner É et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999; 96: 487.

Kobrinsky N, Israels E, Gerrard J et al. Shortening of bleeding time by 1-Deamino-8-D-Arginine Vasopressin in various bleeding disorders. Lancet 1984; 1 (8387): 1145.

Kreuz W, Linde R, Funk M et al. Induction of von Willebrand disease type I by valproic acid. Lancet 1990; 335: 1350-1351.

Kundu SK, Sio R, Mitu A, Ostgaard RA. Evaluation of platelet function by PFA-100. Clin. Chem 1994; 40: 1827-1828.

Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Vorstand und wissenschaftlicher Beirat der bundesärztekammer. Deutscher Ärzteverlag Köln, 3. Auflage 2003

Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-2552.

Macpherson CR, Jacobs P, Dent DM. Abnormal perioperative haemorrhage in asymptomatic patients is not predicted by laboratory testing. S Afr Med J 1993; 83: 106-108.

Mammen E, Comp P, Gosselin R, Greenberg C, Hoots W, Kessler C, Larkin E, Liles D, Nugent D. PFA-100TM System: A new method for assessment of platelet dysfunction. Sem Thromb Haemost 1998; 24: 195-202.

Mannucci P, Remuzzi G, Pusineri F et al. Deamino-8-D-Arginine Vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8.

Mary D, Abid A, Pohlner P et al. The effect of Premarin on blood loss attending open heart surgery. Br J Surg 1976; 63: 196.

Miller CH, Lenzi R, Breen C. Prevalence of von Willebrand's disease among U.S. adults. Blood 1987; 70: 377-378.

O´Brien JR. Familial capillary fragility (Diffuse capillary Teleangiectasia). Proc. Int. Soc. Hematology 1953; 20: 546-548.


[Seite 32↓]

Rapaport S. Preoperative hemostatic evaluation: Which tests, if any ? Blood 1983; 61: 229-231.

Rodeghiero F, Castaman G. Epidemiological investigation of the prevalence of von Willebrand`s disease. Blood 1987; 69: 454.

Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Sem Throm Hemost 1990; 16: 1-20.

Rohrer MJ, Michelotti MC, Nahrwold DL. A prospective evaluation of the efficacy of preoperative coagulation testing. Ann. Surg. 1988; 208: 554-557.

Sack U, Rothe G, Barlage S et al. Durchflußzytometrie in der klinischen Diagnostik J Lab Med 2000; 24: 277-297.

Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-525.

Sadler JE, Mannucci M, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and trteatment of von willwbrand disease. Thromb Haemost 2000; 84: 160-174.

Schulman S, Johnsson H, Egberg N et al. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 1987; 45: 165.

Schulman S, Hjohnsson H, Lindsteft M. Desmopressin as a hemostatic agent in patients with disorders of primary hemostasis. Eur J Surg 1991; 157: 647.

Sheridan D, Card R, Pinilla J et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994; 37: 33.

Soslau G, Horrow J, Brodsky I. The effect of tranexamic acid on platelet ADP during extracorporal circulation. Am J Hematol 1991; 38: 113.

Srámek A, Eikenboom J, Briet E, Vandenbroucke J, Rosendaal F. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155: 1409-1415.

Velanovich V. The value of routine preoperative laboratory testing in predicting postoperative complications: A multivariate analysis. Surgery 1991; 109: 236-243.

Von Willebrand EA. Hereditär Pseudohemofili. Finska Läkarsällskapetes Handl 1926; 67: 7.

Werner E, Broxson E, Tucker E, Giroux D, Shults J, Abshire T. Prevalence of von Willebrand disease in children: Multietnic study. J. of Pediatrics 1993; 123: 893-898.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
16.06.2004